New hope for painful hand and foot skin disease: experimental drug enters trial
NCT ID NCT07503652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new biologic drug called Xeligekimab in 10 adults with moderate to severe palmoplantar pustulosis (PPP), a chronic skin disease causing painful blisters and scales on the palms and soles. The goal is to see if the drug can reduce symptoms and improve quality of life. Participants must have tried other treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of China Medical University
RECRUITINGShenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••